Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
1996-12-26
pubmed:abstractText
Experimental therapeutic regimens for breast cancer include strategies to block the activity of specific oncogenes. Because oncogenesis is a multistep process, specific oncogenes may drive tumor production at one stage yet not function in another. Since the effectiveness of therapy targeted against oncogenes depends on their function in the tumor, correlation of oncogene function to specific stages of tumor development has therapeutic implications. Among the oncogenes known to be important in breast cancer production are two cell surface growth factor receptors, epidermal growth factor receptor (EGFR) and Her2-NEU (NEU). These proteins are receptor tyrosine kinases that autophosphorylate specific tyrosine residues on activation. The oncogenic potential of these receptors depends on this autophosphorylation. We examined 86 primary formalin-fixed, paraffin-embedded breast tumors for overexpression of EGFR and NEU and correlated our findings with the presence of cell surface phosphotyrosine as an indicator of tyrosine kinase activity at the plasma membrane. Our data indicate that only 34% of tumors that overexpress EGFR or NEU show plasma membrane phosphotyrosine, indicating that in the majority of these tumors, the overexpressed oncogene may not be active at this stage.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
0277-3732
pubmed:author
pubmed:issnType
Print
pubmed:volume
19
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
552-7
pubmed:dateRevised
2009-11-19
pubmed:meshHeading
pubmed-meshheading:8931669-Breast Neoplasms, pubmed-meshheading:8931669-Cell Nucleus, pubmed-meshheading:8931669-Cytoplasm, pubmed-meshheading:8931669-Epidermal Growth Factor, pubmed-meshheading:8931669-Epithelium, pubmed-meshheading:8931669-Female, pubmed-meshheading:8931669-Fixatives, pubmed-meshheading:8931669-Formaldehyde, pubmed-meshheading:8931669-Gene Expression Regulation, Neoplastic, pubmed-meshheading:8931669-Humans, pubmed-meshheading:8931669-Membrane Proteins, pubmed-meshheading:8931669-Middle Aged, pubmed-meshheading:8931669-Neoplasm Staging, pubmed-meshheading:8931669-Oncogenes, pubmed-meshheading:8931669-Paraffin Embedding, pubmed-meshheading:8931669-Phosphorylation, pubmed-meshheading:8931669-Phosphotyrosine, pubmed-meshheading:8931669-Protein-Tyrosine Kinases, pubmed-meshheading:8931669-Receptor, Epidermal Growth Factor, pubmed-meshheading:8931669-Receptor, erbB-2, pubmed-meshheading:8931669-Receptor Protein-Tyrosine Kinases, pubmed-meshheading:8931669-Tissue Fixation, pubmed-meshheading:8931669-Tumor Cells, Cultured
pubmed:year
1996
pubmed:articleTitle
Plasma membrane phosphotyrosine, Her2-NEU, and epidermal growth factor receptor in human breast cancer. A comparative study.
pubmed:affiliation
Department of Pathology and Laboratory Medicine, University of Cincinnati, OH 45267-0529, USA.
pubmed:publicationType
Journal Article, Comparative Study